Association of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information system
2008

ACE Inhibitors and Comorbidities in Diabetes

Sample size: 1003 publication Evidence: moderate

Author Information

Author(s): Maria E Ramos-Nino, Charles D MacLean, Benjamin Littenberg

Primary Institution: University of Vermont

Hypothesis

Is there an association between ACE inhibitor therapy and the prevalence of comorbid conditions in adults with diabetes?

Conclusion

ACE inhibitor use is associated with a lower likelihood of a history of cancer and peptic ulcers in patients with diabetes.

Supporting Evidence

  • ACE users reported a history of cancer less frequently than non-users (10% vs. 15%).
  • ACE inhibitors were significantly inversely associated with a personal history of cancer.
  • ACE inhibitors were also inversely associated with peptic ulcer disease.

Takeaway

People with diabetes who take ACE inhibitors are less likely to have had cancer or stomach ulcers.

Methodology

The study surveyed 1003 adults with diabetes, collecting data on comorbidities and medication use through home interviews and direct observation.

Potential Biases

Potential biases may arise from self-reporting of comorbid conditions and the cross-sectional nature of the study.

Limitations

The study is limited by its cross-sectional design, reliance on self-reported diagnoses, and lack of information on the timing and duration of ACE inhibitor use.

Participant Demographics

The study included adults with diabetes from community practices in Northern New England, with a mean age of 64.8 years.

Statistical Information

P-Value

0.01

Confidence Interval

[0.39, 0.89]

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1472-6823-8-17

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication